Korean 3D bioprinting specialist T&R Biofab has patented a way of creating human tissues that could one day be used to develop a heart disease treatment which doesn’t put patients through open surgery. Utilizing T&R Biofab’s process, scientists have already proven it possible to create 100-micrometer cardiac spheroids, capable of regenerating damaged tissues upon transplantation. While the technology remains at a pre-clinical stage, the firm’s patent approval in Japan could now be significant, in that the only developer of something similar in the country, has reportedly licensed it out for $600 million. Imaging showing cardiac fibrosis taking place in spheroid samples after 8 weeks. Image via T&R Biofab. Regenerative cardiac therapy According to CDC heart disease data, cardiac illnesses are the leading cause of death in men and women across most racial and ethnic groups in the US. As such, the development of robust cardiac therapies is a matter of… read more